ClinicalTrials.gg
TerminatedNCT05962788VOCAL-EXTUpdated Feb 10, 2026

Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis

A Phase 3 interventional study of voclosporin in Adolescent Lupus Nephritis and Pediatric Lupus Nephritis, sponsored by Aurinia Pharmaceuticals Inc.. Terminated at 6 sites in 5 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Aurinia Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
DSMB recommendation

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Lupus Nephritis with a site in Mexico — 3 open to participants now, 8 under way, 4 of them phase 3. Lupus Nephritis · Mexico.

Enrollment
32nd of 32
4 · median 132
Started
2024
with 1 other
Phase 3
13 of 32
1 open now
Registered
28th of 32
by date
Lead sponsor
4 of 32
Aurinia Pharmaceuticals Inc.

Among the 32 studies in Lupus Nephritis with a site in Mexico, this one is the 32nd largest by enrollment, is one of 2 that started in 2024, is one of 13 in phase 3, and was the 28th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

3 of the 32 studies in Lupus Nephritis with a site in Mexico are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Lupus Nephritis with a site in Mexico, or all of them as a file.
02

Study summary

The purpose of this study is to assess the long-term safety and tolerability of voclosporin for up to an additional 12 months following completion of treatment in the AUR-VCS-2020-03 study (VOCAL) in adolescent and pediatric subjects with lupus nephritis.

Read the detailed description

This is a 12 month, prospective, multi-center, long-term, open-label extension study of voclosporin in addition to background standard of care with mycophenolate mofetil (MMF) and oral steroids.

Subjects completing participation and treatment with study drug (voclosporin/placebo) of the VOCAL Study (AUR-VCS-2020-03 ; NCT05288855) and meeting all eligibility criteria will receive open-label treatment with voclosporin for approximately 12 months giving a total study treatment duration of 18 months from the start of VOCAL.

All subjects will continue to receive background therapy of MMF and oral corticosteroids starting at the same dose as at completion of the VOCAL study. When clinically indicated, subjects are permitted to be titrated off oral corticosteroids.

03

Conditions studied

  • Adolescent Lupus Nephritis
  • Pediatric Lupus Nephritis

Browse trials for

Keywords

  • voclosporin
  • lupus nephritis
  • calcineurin inhibitors
  • adolescents
  • pediatrics
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written from parent/guardian before any study-specific procedures are performed, if applicable per local regulations.
  • Age-appropriate assent or informed consent from subject before any study-specific procedures are performed.
  • Subjects who have completed 24 weeks of treatment with study drug (voclosporin/placebo) in the VOCAL study. Subjects who had a temporary interruption and were able to successfully re-start study drug will be allowed to enroll after Medical Monitor approval.
  • In the opinion of the Investigator subject requires continued therapy.
  • Subject is willing to continue to take oral MMF for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Currently taking or known need for any of the following medications during the study:

    • Cholestyramine or other drugs that may interfere with enterohepatic recirculation of MMF
    • Calcineurin inhibitors (CNIs) (e.g., cyclosporin and tacrolimus)
    • Strong /5 inhibitors and inducers (e.g., ketoconazole, rifampin, itraconazole, clarithromycin)
  • Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to require dialysis during the study period.
  • A planned kidney transplant within study treatment period.
  • Subjects with any medical condition which in the Investigator's judgement may be associated with increased risk to the subject or may interfere with study assessments or outcomes
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Open Label

    All subjects will receive open label voclosporin initially at the same number of capsules as assigned at Week 24 (End of Study Visit) in AUR-VCS-2020-03 (VOCAL ; NCT05288855). At the Investigator's discretion and after consultation with the Medical Monitor, dose titration up or down in the study will be permitted up to the maximum dose that was studied in AUR-VCS-2020-03.

    Drug: voclosporin

Interventions

  • Subjects will receive 2 capsules (15.8 mg) BID (twice daily), 3 capsules (23.7 mg) BID of voclosporin in addition to standard of care with mycophenolate mofetil (MMF) and steroids.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events (TEAE)

    Incidence (subject counts and event counts) of TEAEs summarized by System Organ Class and Preferred Terms using MedDRA

    Time frame: Per protocol from VOCAL-EXT Study Start to Study Completion plus a 30-day follow-up period

Secondary outcomes

  1. Renal Response

    Proportion of subjects with renal response at Month 12 and 18, defined based on the following parameters: * urine protein creatinine ratio (UPCR) of ≤0.5 mg/mg, and * estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of \>20%, and * Received no rescue medication for lupus nephritis, and * Did not receive \>10 mg/day prednisone for ≥3 consecutive days or for ≥7 days in total prior to the renal response assessment

    Time frame: Per protocol from Study Start to Study Completion plus a 30-day follow-up period

  2. Urine Protein Creatinine Ratio (UPCR)

    Proportion of subjects with UPCR of ≤0.7 mg/mg

    Time frame: Month 12 (VOCAL Study Completion/VOCAL-EXT Study Start) and Month 18 (VOCAL-EXT Study Completion)

  3. Partial Renal Response

    Proportion of subjects in partial renal response as defined by ≥50% reduction from VOCAL baseline in UPCR

    Time frame: Month 12 (VOCAL Study Completion/VOCAL-EXT Study Start) and Month 18 (VOCAL-EXT Study Completion)

07

Study locations

6 sites
  • UNC-Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Clinica de la Costa S.A.S
    Barranquilla, Atlántico 76100, Colombia
  • Yokohama City University Hospital
    Yokohama, Kanagawa, Japan
  • Centro de Especialidades Medicas del Sureste
    Mérida, Yucatán 97000, Mexico
  • Hospital Infantil de México Federico Gómez
    Mexico City, 06720, Mexico
  • Siriraj Hospital
    Bangkok, 10700, Thailand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Jul 2025, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2023
First posted
Jul 27, 2023
StartActual
Mar 28, 2024
Primary completionActual
Jul 4, 2025
CompletionActual
Jul 4, 2025
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05962788
Lead sponsor
Aurinia Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Jul 27, 2023
Start date
Mar 28, 2024
Primary completion
Jul 4, 2025
Completion
Jul 4, 2025
Last update
Feb 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voclosporin

Start the discussion